Impact of COPD Exacerbations and Burden of Disease in Spain: AVOIDEX Study

References

• World Health Organization (WHO). Chronic respiratory diseases; 2021. Available from: https://www.who.int/westernpacific/health-topics/chronic-respiratory-diseases. Accessed July 19, 2021.
   Google Scholar
• European Respiratory Society. The burden of lung disease; 2013. Available from: https://www.erswhitebook.org/chapters/the-burden-of-lung-disease/. Accessed July 19, 2021.
   Google Scholar
• Soriano JB, Kendrick PJ, Paulson KR, et al. Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Respir Med. 2020;8(6):585–596.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstuctuve Lung DIsease (GOLD). Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease; 2022. Available from: https://goldcopd.org/wp-content/uploads/2021/12/GOLD-REPORT-2022-v1.1-22Nov2021_WMV.pdf. Accessed February 10, 2022.
   Google Scholar
• Ritchie AI, Wedzicha JA. Definition, causes, pathogenesis, and consequences of chronic obstructive pulmonary disease exacerbations. Clin Chest Med. 2020;41(3):421–438. doi:10.1016/j.ccm.2020.06.007
   PubMed Web of Science ®Google Scholar
• Viniol C, Vogelmeier CF. Exacerbations of COPD. Eur Respir Rev. 2018;27:147. doi:10.1183/16000617.0103-2017
   Web of Science ®Google Scholar
• Vogelmeier CF, Román-Rodríguez M, Singh D, Han MK, Rodríguez-Roisin R, Ferguson GT. Goals of COPD treatment: focus on symptoms and exacerbations. Respir Med. 2020;166:105938. doi:10.1016/j.rmed.2020.105938
   PubMed Web of Science ®Google Scholar
• Bollmeier SG, Hartmann AP. Management of chronic obstructive pulmonary disease: a review focusing on exacerbations. Am J Health Syst Pharm. 2020;77(4):259–268. doi:10.1093/ajhp/zxz306
   PubMed Web of Science ®Google Scholar
• Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000;320(7245):1297–1303. doi:10.1136/bmj.320.7245.1297
   PubMed Web of Science ®Google Scholar
• Calverley PMA, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775–789. doi:10.1056/NEJMoa063070
   PubMed Web of Science ®Google Scholar
• Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128–1138. doi:10.1056/NEJMoa0909883
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). Chronic obstructive pulmonary disease in over 16s: diagnosis and management; 2019. Available from: https://www.nice.org.uk/guidance/ng115. Accessed July 19, 2021.
   Google Scholar
• Casanova C, de Torres JP, Aguirre-Jaíme A, et al. The progression of chronic obstructive pulmonary disease is heterogeneous: the experience of the BODE cohort. Am J Respir Crit Care Med. 2011;184(9):1015–1021. doi:10.1164/rccm.201105-0831OC
   PubMed Web of Science ®Google Scholar
• Halpin DM, Miravitlles M, Metzdorf N, Celli B. Impact and prevention of severe exacerbations of COPD: a review of the evidence. Int J Chron Obstruct Pulmon Dis. 2017;12:2891–2908. doi:10.2147/COPD.S139470
   PubMed Web of Science ®Google Scholar
• Hurst JR, Skolnik N, Hansen GJ, et al. Understanding the impact of chronic obstructive pulmonary disease exacerbations on patient health and quality of life. Eur J Intern Med. 2020;73:1–6. doi:10.1016/j.ejim.2019.12.014
   PubMed Web of Science ®Google Scholar
• Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157(5 Pt 1):1418–1422. doi:10.1164/ajrccm.157.5.9709032
   PubMed Web of Science ®Google Scholar
• Rehman AU, Ahmad Hassali MA, Muhammad SA, et al. The economic burden of chronic obstructive pulmonary disease (COPD) in the USA, Europe, and Asia: results from a systematic review of the literature. Expert Rev Pharmacoecon Outcomes Res. 2020;20(6):661–672. doi:10.1080/14737167.2020.1678385
   PubMed Web of Science ®Google Scholar
• Iheanacho I, Zhang S, King D, Rizzo M, Ismaila AS. Economic burden of chronic obstructive pulmonary disease (COPD): a systematic literature review. Int J Chron Obstruct Pulmon Dis. 2020;15:439–460. doi:10.2147/COPD.S234942
   PubMed Web of Science ®Google Scholar
• Pasquale MK, Sun SX, Song F, Hartnett HJ, Stemkowski SA. Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly Medicare population. Int J Chron Obstruct Pulmon Dis. 2012;7:757–764. doi:10.2147/COPD.S36997
   PubMed Web of Science ®Google Scholar
• Price LC, Lowe D, Hosker HSR, et al. UK National COPD Audit 2003: impact of hospital resources and organisation of care on patient outcome following admission for acute COPD exacerbation. Thorax. 2006;61(10):837–842. doi:10.1136/thx.2005.049940
   PubMed Web of Science ®Google Scholar
• Sicras-Mainar A, Enriquez JL, Hernández I, Sicras-Navarro A, Aymerich T, Leon M. PMU146 Validation and representativeness of the Spanish BIG-PAC database: integrated computerized medical records for research into epidemiology, medicines and health resource use (real world evidence). Value Health. 2019;22:S734. doi:10.1016/j.jval.2019.09.1764
   Web of Science ®Google Scholar
• Sicras-Mainar A, Sicras-Navarro A, Palacios B, Varela L, Delgado JF. Epidemiología y tratamiento de la insuficiencia cardiaca en España: estudio PATHWAYS-HF. Rev Esp Cardiol. 2020;149(6):240–247. doi:10.1016/j.recesp.2020.09.014
   Google Scholar
• Ministerio de S, Consumo y bienestar social. international classification of diseases (9th edition) clinical modification (ICD-09-CM); 2021. Available from: https://eciemaps.mscbs.gob.es/ecieMaps/browser/index_9_mc.html. Accessed June 11, 2021.
   Google Scholar
• World Health Organization (WHO). The anatomical therapeutic chemical classification system with defined daily doses (ATC/DDD). Available from: https://www.who.int/standards/classifications/other-classifications/the-anatomical-therapeutic-chemical-classification-system-with-defined-daily-doses. Accessed April 8, 2021.
   Google Scholar
• Miravitlles M, Soler-Cataluña JJ, Soriano JB, et al. Determinants of blood eosinophil levels in the general population and patients with COPD: a population-based, epidemiological study. Respir Res. 2022;23(1):49. doi:10.1186/s12931-022-01965-3
   PubMed Web of Science ®Google Scholar
• Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60(11):925–931. doi:10.1136/thx.2005.040527
   PubMed Web of Science ®Google Scholar
• Izquierdo JL, Morena D, González Y, et al. Clinical management of COPD in a real-world setting. a big data analysis. Arch Bronconeumol. 2021;57(2):94–100. doi:10.1016/j.arbr.2019.12.023
   PubMed Web of Science ®Google Scholar
• Pozo-Rodríguez F, López-Campos JL, Alvarez-Martínez CJ, et al. Clinical Audit of COPD Patients Requiring Hospital Admissions in Spain: AUDIPOC Study. PLos One. 2012;7(7):e42156. doi:10.1371/journal.pone.0042156
   PubMed Web of Science ®Google Scholar
• Cazzola M, Rogliani P, Calzetta L, Matera MG. Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis. Eur Respir J. 2018;52(6):1801586. doi:10.1183/13993003.01586-2018
   PubMed Web of Science ®Google Scholar
• Vanfleteren L, Fabbri LM, Papi A, Petruzzelli S, Celli B. Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal. Int J Chron Obstruct Pulmon Dis. 2018;13:3971–3981. doi:10.2147/COPD.S185975
   PubMed Web of Science ®Google Scholar
• Fenwick E, Martin A, Schroeder M, et al. Cost-effectiveness analysis of a single-inhaler triple therapy for COPD in the UK. ERJ Open Res. 2021;7:1. doi:10.1183/23120541.00480-2020
   Google Scholar
• Buendía JA, Patiño DG. Cost-utility of triple versus dual inhaler therapy in moderate to severe asthma. BMC Pulm Med. 2021;21(1):398. doi:10.1186/s12890-021-01777-z
   PubMed Web of Science ®Google Scholar
• Paly V, Vallejo-Aparicio LA, Gabrio A, Baio G, Martin A, Ismaila A. IMPACT: healthcare resource use data and associated costs for single-inhaler triple therapy versus dual therapies in Spain. Eur Respir J. 2021;58(suppl):65. doi:10.1183/13993003.congress-2021.OA4283
   Google Scholar